Table 5.
Univariate analysis for one-month mortality: significant variable.
| Parameter | Day 30 survival N: 94 | Day 30 mortality N: 76 | p |
|---|---|---|---|
| IVIG | |||
| Yes | 7 (7.5%) | 15 (19.7%) | 0.017 |
| No | 87 (92.5%) | 61 (80.3%) | |
| Carbapenem including therapy anytime during the COVID-19/FEN episode | |||
| Yes | 50 (53.2%) | 57 (75%) | 0.003 |
| No | 44 (46.8%) | 19 (25%) | |
| Supplemental oxygen | |||
| Yes | 60 (63.8%) | 67 (88.2%) | < 0.001 |
| No | 34 (36.2%) | 9 (11.8%) | |
| Mechanical ventilation | |||
| Yes | 2 (2.1%) | 42 (55.3%) | < 0.001 |
| No | 92 (97.9%) | 34 (44.7%) | |
| Septic shock during COVID-19/FEN | |||
| Yes | 5 (5.3%) | 29 (38.2%) | < 0.001 |
| No | 89 (94.7%) | 47 (61.8%) | |
| Need for ICU during COVID-19/FEN | |||
| Yes | 12 (12.8%) | 47 (61.8%) | < 0.001 |
| No | 82 (87.2%) | 29 (38.2%) | |
| Chronic renal failure | |||
| Yes | 0 (0%) | 7 (9.2%) | 0.002 |
| No | 94 (100%) | 69 (90.8%) | |
| Neutrophil (/mm3) | 296 ± 205 | 230 ± 172 | 0.026 |
| CRP (mg/L) | 89 ± 118 | 130 ± 90 | 0.013 |
| CRP ≥ 75 mg/L | 50 (53.2%) | 58 (76.3%) | < 0.001 |
| CRP < 75 mg/L | 44 (46.8%) | 18 (23.7%) | |
| CRP ≥ 100 mg/L | 38 (40.4%) | 50 (65.8%) | 0.001 |
| CRP < 100 mg/L | 56 (59.4%) | 26 (34.2%) | |
| D-dimer (µg/L) | 1355 ± 1729 | 2823 ± 5479 | 0.015 |
| D-dimer < 1000 µg/L | 54 (60.7%) | 30 (44.1%) | 0.039 |
| D-dimer ≥ 1000 µg/L | 35 (39.3%) | 38 (55.9%) | |
| Ferritin (µg/L) | 1124 ± 1658 | 2754 ± 6091 | 0.013 |
| LDH (U/L) | 307 ± 213 | 412 ± 405 | 0.031 |
| High risk FEN MASCC (< 21) | 28 (29.8%) | 43 (56.6%) | < 0.001 |
| Low risk FEN MASCC (≥ 21) | 66 (70.2%) | 33 (43.4%) | |
IVIG intravenous immunoglobulin, FEN febrile neutropenia, ICU intensive care unit, CRP C-reactive protein, LDH lactate dehydrogenase, MASCC Multinational Association of Supportive Care in Cancer.